EyePoint Pharmaceuticals (NASDAQ: EYPT) is a clinical-stage ophthalmic biopharmaceutical company focused on developing sustained-release drug delivery treatments for serious retinal diseases. Its primary pipeline asset is DURAVYU, a sustained-release intravitreal insert containing vorolanib, in Phase 3 trials for wet age-related macular degeneration (wet AMD) and in Phase 2/3 development for diabetic macular edema (DME) as of the 10-K filed March 5, 2026. Revenue has historically come from license and collaboration arrangements, including upfront license fees, milestone payments, and royalties on partner product sales. The company previously held royalty rights on ILUVIEN, a corticosteroid implant licensed to ANI Pharmaceuticals, but sold those royalty rights to SWK Funding, LLC in December 2020 for a one-time $16.5 million payment. EyePoint operates under ongoing DOJ and HHS scrutiny related to a federal healthcare investigation, with settlement agreements expected in the first half of 2026. Jay S. Duker, M.D. serves as President and CEO, as of March 5, 2026.

Revenue model

License and collaboration revenue from upfront payments recognized at delivery of intellectual property, milestone payments tied to specified development or regulatory objectives, and sales-based royalties from partner commercialization. The ILUVIEN royalty stream was monetized via a one-time $16.5 million sale to SWK Funding, LLC in December 2020.

Products and services

DURAVYU (vorolanib intravitreal insert): Phase 3 in wet AMD, Phase 2/3 in DME as of March 5, 2026. ILUVIEN: corticosteroid intravitreal implant licensed to ANI Pharmaceuticals for diabetic macular edema and uveitis indications; EyePoint's royalty interest was sold to SWK Funding, LLC in December 2020.

Customers and end markets

End markets are retinal disease patients, specifically those with wet AMD and DME. Prescribers are ophthalmologists and retinal specialists. Licensing partners and collaborators serve as the direct commercial customers in the revenue model.

Value-chain role

Drug developer and licensor. EyePoint conducts internal clinical development and relies on third-party contract manufacturers, clinical research organizations, and licensing partners for commercialization. It does not directly commercialize products in the current pipeline stage.

Geographic exposure

Primarily U.S.-based operations. Subject to U.S. federal and state privacy regulations, EU GDPR, and UK GDPR, suggesting some international operational scope, but no specific non-U.S. revenue geography is disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-05

Industry: Laboratory Analytical Instruments Peers: AN2 Therapeutics Inc Biote Corp Oramed Pharmaceuticals Inc Johnson & Johnson MARINUS PHARMACEUTICALS, INC. OptiNose, Inc. RVL Pharmaceuticals plc Satsuma Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.